New drug tested for rare 'Cold Allergy' disease
NCT ID NCT07247266
Summary
This early-stage study is testing a new drug called JTE-162 for people with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare genetic inflammatory disease. The study will check if the drug is safe and if it reduces inflammation and symptoms like rash, joint pain, and fever. Only 5 participants will take the drug daily for 2 weeks while researchers monitor their health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gordon Sussman Clinical Research Inc.
RECRUITINGNorth York, Ontario, M3B 3S6, Canada
Conditions
Explore the condition pages connected to this study.